Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Radiotherapy Combined With Atezolizumab and Bevacizumab in Unresectable HCC
NCT06133062Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Nov 2023
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Nov 2023; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06133062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133062.